Dermoscopic features associated with 3-GEP PLA: LINC00518, PRAME, and TERT expression in suspicious pigmented lesions

A signature of seven hypoxia-related lncRNAs is a potential biomarker for predicting the prognosis of melanoma

Melanoma is the most aggressive type of skin cancer and has a high mortality rate once metastasis occurs. Hypoxia is a universal characteristic of the microenvironment of cancer and a driver of melanoma progression. In recent years, long noncoding RNAs (lncRNAs) have attracted widespread attention in oncology research. In this study, screening was performed and revealed seven hypoxia-related lncRNAs AC008687.3, AC009495.1, AC245128.3, AL512363.1, LINC00518, LINC02416 and MCCC1-AS1 as predictive biomarkers. A predictive risk model was constructed via univariate Cox regression analysis, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses. Patients were grouped according to the model risk score, and Kaplan-Meier analysis was performed to compare survival between groups. Functional and pathway enrichment analyses were performed to compare gene set enrichment between groups. Moreover, a nomogram was constructed with the risk score as a variable. In both the training and validation sets, patients in the low-risk group had better overall survival than did those in the high-risk group (P<0.001). The 3-, 5- and 10-year area under the curve (AUC) values for the nomogram model were 0.821, 0.795 and 0.820, respectively. Analyses of immune checkpoints, immunotherapy response, drug sensitivity, and mutation landscape were also performed. The results suggested that the low-risk group had a better response to immunotherapeutic. In addition, the nomogram can effectively predict the prognosis and immunotherapy response of melanoma patients. The signature of seven hypoxia-related lncRNAs showed great potential value as an immunotherapy response biomarker, and these lncRNAs might be treatment targets for melanoma patients.

DDCNN-F: double decker convolutional neural network 'F' feature fusion as a medical image classification framework

Melanoma is a severe skin cancer that involves abnormal cell development. This study aims to provide a new feature fusion framework for melanoma classification that includes a novel 'F' Flag feature for early detection. This novel 'F' indicator efficiently distinguishes benign skin lesions from malignant ones known as melanoma. The article proposes an architecture that is built in a Double Decker Convolutional Neural Network called DDCNN future fusion. The network's deck one, known as a Convolutional Neural Network (CNN), finds difficult-to-classify hairy images using a confidence factor termed the intra-class variance score. These hirsute image samples are combined to form a Baseline Separated Channel (BSC). By eliminating hair and using data augmentation techniques, the BSC is ready for analysis. The network's second deck trains the pre-processed BSC and generates bottleneck features. The bottleneck features are merged with features generated from the ABCDE clinical bio indicators to promote classification accuracy. Different types of classifiers are fed to the resulting hybrid fused features with the novel 'F' Flag feature. The proposed system was trained using the ISIC 2019 and ISIC 2020 datasets to assess its performance. The empirical findings expose that the DDCNN feature fusion strategy for exposing malignant melanoma achieved a specificity of 98.4%, accuracy of 93.75%, precision of 98.56%, and Area Under Curve (AUC) value of 0.98. This study proposes a novel approach that can accurately identify and diagnose fatal skin cancer and outperform other state-of-the-art techniques, which is attributed to the DDCNN 'F' Feature fusion framework. Also, this research ascertained improvements in several classifiers when utilising the 'F' indicator, resulting in the highest specificity of + 7.34%.